We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
126
Gossamer Bio
GOSS
$87M
$411K 0.07%
416,958
-115,670
-22% -$111K
CASI
127
DELISTED
CASI Pharmaceuticals
CASI
$399K 0.07%
64,835
+56,595
+687% +$366K
ADGM
128
Adagio Medical Holdings
ADGM
$15.2M
$384K 0.06%
+148,861
New +$709K
SAGE
129
DELISTED
Sage Therapeutics
SAGE
$373K 0.06%
+51,650
New +$473K
CNTA
130
DELISTED
Centessa Pharmaceuticals
CNTA
$373K 0.06%
23,302
-229,895
-91% -$2.82M
CAPR icon
131
Capricor Therapeutics
CAPR
$237M
$370K 0.06%
+24,307
New +$120K
SYRE icon
132
Spyre Therapeutics
SYRE
$9.25B
$369K 0.06%
12,560
-22,620
-64% -$630K
ACAD icon
133
Acadia Pharmaceuticals
ACAD
$5.03B
$355K 0.06%
23,100
+21,800
+1,677% +$364K
BMRN icon
134
CALL
BioMarin Pharmaceuticals
BMRN
$12.3B
$351K 0.06%
+5,000
New +$418K
TXG icon
135
10x Genomics
TXG
$6.61B
$339K 0.06%
+15,000
New +$310K
RNXT icon
136
RenovoRx
RNXT
$50.5M
$334K 0.05%
315,192
-40,048
-11% -$44.9K
OAKU
137
DELISTED
Oak Woods Acquisition Corp
OAKU
$333K 0.05%
30,000
– –
ACLX
138
DELISTED
Arcellx
ACLX
$331K 0.05%
3,962
+3,862
+3,862% +$257K
PYPD icon
139
PolyPid
PYPD
$92.8M
$323K 0.05%
93,902
-10,048
-10% -$36.1K
JVSA
140
DELISTED
JV SPAC Acquisition Corp
JVSA
$310K 0.05%
+30,000
New +$307K
ABCL icon
141
AbCellera Biologics
ABCL
$2.12B
$299K 0.05%
+114,981
New +$319K
JSPR icon
142
Jasper Therapeutics
JSPR
$23.6M
$297K 0.05%
+15,816
New +$315K
IMVT icon
143
CALL
Immunovant
IMVT
$8.25B
$291K 0.05%
+10,200
New +$301K
TRML
144
DELISTED
Tourmaline Bio
TRML
$289K 0.05%
11,260
-9,800
-47% -$164K
VRNA
145
DELISTED
Verona Pharma
VRNA
$288K 0.05%
+10,000
New +$246K
YARW
146
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$287K 0.05%
3,057
-367
-11% -$34.8K
DCTH icon
147
Delcath Systems
DCTH
$522M
$280K 0.05%
31,052
-167,295
-84% -$1.45M
ORKA
148
Oruka Therapeutics
ORKA
$5.96B
$274K 0.04%
11,187
+4,131
+59% +$144K
BCRX icon
149
BioCryst Pharmaceuticals
BCRX
$2.4B
$266K 0.04%
35,000
+5,600
+19% +$42.6K
INSM icon
150
Insmed
INSM
$28.6B
$265K 0.04%
3,634
-38,583
-91% -$2.85M
4 5
6
7 8

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.